Showing 5511-5520 of 6035 results for "".
- New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meetinghttps://modernod.com/news/new-combined-data-from-the-phase-2-and-phase-3-teprotumumab-clinical-trials-to-be-presented-during-the-american-thyroid-association-annual-meeting/2477038/New pooled data from the phase 2 and phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oc
- Julia A. Haller, MD, Elected to National Academy of Medicinehttps://modernod.com/news/julia-a-haller-md-elected-to-national-academy-of-medicine/2477033/Wills Eye Hospital announced its Ophthalmologist-in-Chief, Julia A. Haller, MD, has been elected to the National Academy of Medicine (NAM), considered one of the highest honors in the fields of health and medicine, recognizing individuals who have demonstrated outstanding professional achievement
- Bausch Health Licenses Clearside Biomedical’s Xipere, An Investigational Treatment For Macular Edema Associated With Uveitishttps://modernod.com/news/bausch-health-licenses-clearside-biomedicals-xipere-an-investigational-treatment-for-macular-edema-associated-with-uveitis/2477035/Bausch Health Companies announced that an affiliate of Bausch Health has acquired an exclusive license for the commercialization and development of Xipere (triamcinolone acetonide suprachoroidal injectable suspension) in the United States and
- New Hope for Patients With Vision Loss at SAVIR-Center for Vision Restorationhttps://modernod.com/news/new-hope-for-patients-with-vision-loss-at-savir-center-for-vision-restoration/2477031/Persistent psychological stress, which is widely recognized as a consequence of vision loss, is also a major contributor to its development and progression, according to a study published in the EPMA Journal, the official journal of the European Association for Predictive, Preventive, and
- Wolfgang Haigis—Scientist Known for His Formulae—Dies at 72https://modernod.com/news/wolfgang-haigis-scientist-known-for-his-formulae-dies-at-72/2477025/The German Society for Cataract and Refractive Surgery (DGII) has announced that Prof. Dr. Wolfgang Haigis, a physicist working at the University of Wurzburg, died on October 15 at the age of 72. Dr. Haigis was a pioneer and a driving force in the development and the refinement of biometry
- Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at AAOhttps://modernod.com/news/aura-biosciences-announces-updated-phase-1b-2-clinical-data-for-au-011-presented-at-aao/2477015/Aura Biosciences announced the presentation of updated clinical data from its ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the company’s lead product candidate for the first line treatment of primary choroidal melanoma, at the American Academy of
- Sleep Apnea Linked to Blinding Eye Disease in People with Diabeteshttps://modernod.com/news/sleep-apnea-linked-to-blinding-eye-disease-in-people-with-diabetes/2477016/New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes
- Using AI to Screen for Diabetic Eye Disease Feasible in the Real Worldhttps://modernod.com/news/using-ai-to-screen-for-diabetic-eye-disease-feasible-in-the-real-world/2477017/New research shows that an automated, artificial intelligence (AI) screening system accurately detects diabetic retinopathy 95.5 percent of the time. The system doesn’t require the input of an expert ophthalmologist and it can provide a reading in 60 seconds, making real-time screening possible f
- Eyevance Pharmaceuticals Acquires Tobradex ST and Natacynhttps://modernod.com/news/eyevance-pharmaceuticals-acquires-tobradex-st-and-natacyn/2477011/Eyevance Pharmaceuticals has announced the acquisition of Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% and Natacyn (natamycin ophthalmic suspension) 5% from Novartis. Terms of the deal were not disclosed. “The acquisition of Tobradex ST and Natacyn further
- Luneau Technology Acquires Next Sight to Enter Telehealth Markethttps://modernod.com/news/luneau-technology-acquires-next-sight-to-enter-telehealth-market/2477007/Luneau Technology group announced that it has acquired Padova, Italy-based Next Sight, maker of the Nexy retinal screening device. Terms of the deal were not disclosed. The acquisition brings to Luneau increased capabilities–covering both back and front of the eye. Luneau develops,